부산대학교 도서관

Half of the global overweight/obese adult population have metabolic-dysfunction-associated fatty liver disease (MAFLD),1 with prevalence rising, even among non-obese individuals.2,3 This increase is observed globally and mostly in low- and low-middle-income countries of Africa, Asia and South America and represents a great worldwide burden on healthcare expenditures.4-7 Lifestyle changes and a healthy diet are still the cornerstone in the clinical management of these patients as approved medications are presently lacking.4,8 In clinical settings, most patients with fatty liver disease are first identified and subsequently followed up in the community by primary care practitioners (PCPs).9 There is unequivocal evidence of the health-promoting influence of primary care and its role in the prevention of illness and death.10 In addition, in contrast to speciality care, primary care is characterized by a more equitable distribution as a healthcare service for all populations.10 In this context, primary care is central and may therefore help or hinder optimal chronic disease care. In fact, since PCPs play a crucial role in the early detection of fatty liver disease and the prevention of clinical progression and potential complications, their appropriate evaluation of fatty liver disease is paramount. Simplification of the diagnostic criteria for fatty liver disease suitable for a busy primary care environment is needed to enable treatment expansion into primary care at a larger scale.34 These criteria need to be both useful and practical, and their content should be guided by input from clinicians involved in the daily care of these patients, particularly PCPs. Therefore, it is crucial to understand PCP perspectives regarding the proposed redefinition of fatty liver disease as well as the implications for the primary care of patients. [Extracted from the article]